sotatercept

Gossamer could put pressure on Merck
Gossamer could put pressure on Merck
EP Vantage
Merck
Gossamer Bio
PAH
sotatercept
United Therapeutics
ralinepag
Flag link:
Sotatercept- the breakthrough PAH has been waiting for?
Sotatercept- the breakthrough PAH has been waiting for?
Clinical Trials Arena
Merck
sotatercept
Acceleron
PAH
Flag link:
Is Merck Moving Toward Another Blockbuster Drug Launch?
Is Merck Moving Toward Another Blockbuster Drug Launch?
Motley Fool
Merck
sotatercept
PAH
Flag link:
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Merck nails phase 3 sotatercept win, making good on its $11.5B Acceleron buy
Fierce Biotech
Merck
Acceleron
clinical trials
sotatercept
PAH
pulmonary arterial hypertension
Flag link:
Merck & Co justifies paying up for Acceleron
Merck & Co justifies paying up for Acceleron
EP Vantage
Merck
Accleron
M&A
sotatercept
Reblozyl
PAH
Flag link:
Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report
Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report
Endpoints
Merck
Acceleron
M&A
PAH
sotatercept
Flag link:
Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign
Acceleron uncorks more mid-stage data for PAH drug sotatercept as part of the drug's resurrection campaign
Endpoints
Acceleron
sotatercept
PAH
Flag link:
Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
Endpoints
Acceleron
PAH
FDA
breakthrough therapy
sotatercept
Flag link:
Acceleron’s post-Reblozyl plan comes together
Acceleron’s post-Reblozyl plan comes together
EP Vantage
Acceleron
sotatercept
PAH
JNJ
Bellerophon Therapeutics
United Therapeutics
Vivus
Arena
Novartis
Flag link:
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
Motley Fool
Acceleron
PAH
clinical trials
sotatercept
Flag link:
Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension
Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension
Pharmaceutical Business Review
Acceleron
orphan drugs
sotatercept
PAH
Flag link:
Celgene anemias treatment granted FDA orphan designation
Celgene anemias treatment granted FDA orphan designation
Yahoo/Fly on the Wall
FDA
Celgene
anemia
sotatercept
Flag link:
Acceleron, Celgene Vs. Amgen In The Anemia Drug Race
Acceleron, Celgene Vs. Amgen In The Anemia Drug Race
Seeking Alpha
Amgen
Acceleron
Celgene
anemia
sotatercept
ACE-536
Flag link: